SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Northwest Biotherapeutics Inc.
An SI Board Since August 2006
Posts SubjectMarks Bans Symbol
760 18 0 NWBO
Emcee:  John McCarthy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
660siliconinvestor.com Well, of course, since you've now quoted me out of contJohn McCarthy-3/23/2015
659siliconinvestor.com Thanks Senti! I had forgotten about the Choi criteria in paJohn McCarthy-3/23/2015
658Upcoming Events March 26th itoc-conference.eu "Proffered Paper: ProlongJohn McCarthy-3/23/2015
657Oh yes, you saw a regulation. Below is what I sent you before. Before you read tJohn McCarthy-3/19/2015
656See 2.5.1 - 2.5.7: fda.gov siliconinvestor.comJohn McCarthy-3/19/2015
655I'm sorry but I saw no "regulation." My mistake was not whether thJohn McCarthy-3/19/2015
654I think you mean "quantifiers." I listed four for the Directtrial, theJohn McCarthy-3/19/2015
653There are a minimum of four quantifiers for response in patients in the direct tJohn McCarthy-3/19/2015
652Hi Antii, I'm not trying to red ink your thoughtful message, but I sometimesJohn McCarthy-3/19/2015
651Oh yes, I'm beginning to "see" it! ;) Here are a few quick bits John McCarthy-3/19/2015
650t's my singular gyrus, I can't help it! ;) Here I'll try to "eJohn McCarthy-3/19/2015
649For the Ph II, RECIST criteria is still the primary means by which a response ofJohn McCarthy-3/19/2015
648From Cancer Compass board on Dendritic cell vaccines in Germany with Dr. NesslehJohn McCarthy-3/19/2015
647Lot of good discussion here lately. Here's my opinion. From the latest absJohn McCarthy-3/19/2015
646Let me try to break down the RECIST thing a bit. Say a patient has 5 measurablJohn McCarthy-3/18/2015
645Well, here you go folks. The abstract body from the AACR conf. This was submittJohn McCarthy-3/18/2015
644Regarding RECIST and the P1 Direct Trial… There has been quite a bit of discussJohn McCarthy-3/17/2015
643What do you mean they will not ignore it? Or more appropriately, why would they John McCarthy-3/17/2015
642Also if approved they can run as many Ph III label extension studies that they wJohn McCarthy-3/16/2015
641cibmtr.orgJohn McCarthy-3/16/2015
640 Pyrrhonian[graphic] Saturday, 03/14/15 01:55:02 PM Re: koman post# 30718 Post John McCarthy-3/14/2015
639HE announcement may be getting closer than we all think. My expectation was reimJohn McCarthy-3/11/2015
638Not sure your math is correct on YMB. The MOS is calculated from two different sJohn McCarthy-3/10/2015
637More accurate calculation below: Equation: 19 x 15.1 + 8 x 14.7 + 28 x Y = 55 x John McCarthy-3/10/2015
636rapid progressors Results and conclusion The results obtained in two cohorts oJohn McCarthy-3/10/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News